Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mifepristone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | PGR known ✓ | P06401 | 10/20 | 1.00 |
| ▸ | AR | P10275 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mifepristone SCHEMBL19236544 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL13110930 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL19100510 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL13840946 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL16087 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL10622661 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL10625406 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL10607607 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL20769786 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL14870641 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235603-A1 | METHODS, DOSING REGIMENS AND MEDICATIONS USING ANTI-PROGESTATIONAL AGENTS FOR THE TREATMENT OF DISORDERS | LABORATOIRE HRA-PHARMA (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20130331366-A1 | METHODS, DOSING REGIMENS AND MEDICATIONS USING ANTI-PROGESTATIONAL AGENTS FOR THE TREATMENT OF DISORDERS | DANCO LABORATORIES LLC (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2137314-B1 | NEW MODULATING MOLECULES FOR AN IMPROVED REGULATED EXPRESSION SYSTEM | BAYER IP GMBH (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20120115831-A1 | METHODS, DOSING REGIMENS AND MEDICATIONS USING ANTI-PROGESTATIONAL AGENTS FOR THE TREATMENT OF DISORDERS | LABORATOIRE HRA PHARMA, SA (FR) | 2012-05-10 | — | — | US | disclosed |
| US-8173626-B2 | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders | DANCO LABORATORIES LLC (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2011082231-A1 | COMPOSITIONS AND METHODS FOR PROMOTING EPITHELIALIZATION AND WOUND CLOSURE | NEW YORK UNIVERSITY (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110020925-A1 | NEW MODULATING MOLECULES FOR AN IMPROVED REGULATED EXPRESSION SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2137314-A2 | NEW MODULATING MOLECULES FOR AN IMPROVED REGULATED EXPRESSION SYSTEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008125280-A2 | NEW MODULATING MOLECULES FOR AN IMPROVED REGULATED EXPRESSION SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125222-A2 | NEW MODULATION MOLECULES FOR AN IMPROVED REGULATED EXPRESSION SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2006122972-A1 | INTERFERON-BETA GENE THERAPY USING AN IMPROVED, REGULATED EXPRESSION SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-11-23 | — | — | WO | disclosed |
| EP-1551860-A1 | GLUCOCORTICOID RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040167110-A1 | Methods for treating gastroesophageal reflux disease | CORCEPT THERAPEUTICS, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| EP-0792152-B1 | METHODS OF CONTRACEPTION | BALANCE PHARMACEUTICALS INC (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004000869-A1 | GLUCOCORTICOID RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| US-20020151588-A1 | Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1212330-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20010016578-A1 | Eliminates problems associated with prolonged therapy associated with estrogenic steroids, progesterone synthesis inhibitor; counteract endometrial hyperstimulation, hyperplasia or carcinoma | BALANCE PHARMACEUTICALS, INC. | 2001-08-23 | — | — | US | disclosed |
| US-6225298-B1 | Compositions and methods for contraception and for treatment of benign gynecological disorders | BALANCE PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2001016139-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151588-A1 | Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 153/4885AR 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.